Here's Why Exelixis (EXEL) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • 21 hours ago

EXEL Down on Colorectal Cancer Study Data on Zanzalintinib

Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.

Zacks Investment Research • 17 hours ago

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver metastases, NLM) in the phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).

Business Wire • Jun 22, 2026

Here's Why Exelixis (EXEL) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 19, 2026

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jun 18, 2026

Exelixis Hits High on Growing Sales, Institutional Inflows

Drug adoption and a strong pipeline see institutions send Exelixis, Inc. (EXEL) shares to all-time highs.

FXEmpire • Jun 10, 2026

Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 9, 2026

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 4, 2026

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026

Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 3, 2026